H.C. Wainwright lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm says Voxzogo’s Q3 miss reflects order timing as demand remains intact ahead of oral entrants.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Strong Growth Potential Amidst Competitive Challenges
- BioMarin price target lowered to $70 from $90 at Wells Fargo
- BioMarin price target lowered to $80 from $86 at Barclays
- BioMarin Reports Strong Q3 2025 Revenue Growth
- BioMarin Pharmaceutical: Strategic Adjustments and Future Potential Justify Buy Rating Despite Revenue Miss